Invivogen
Menu

Raji-hPD-L1 Cells

Raji-hPD-L1 Cells Unit size Cat. code Docs Qty Price
Human lymphoblast cells - ADCC PD-L1 Target Cells
3-7 x 10e6 cells
raji-hpdl1
+-
$1,102.00

You may also need : Anti-hPD-L1-hIgG1 | View more associated products

Raji-hPD-L1-application
Examples of applications using the Raji-hPD-L1 cell line.

NEW PRODUCT

Human PD-L1-expressing B-cell line

Raji-hPD-L1  cells were developed from the human Raji cell line. Raji cells have been successfully used as target cells in  human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, Natural Killer cells, or Jurkat-derived reporter T cells. PD-L1 (programmed cell death  ligand 1; also known as CD274 or B7-H1) is a transmembrane protein expressed at the cell surface of hematopoietic and nonhematopoietic cells, and is induced by pro-inflammatory cytokines, such as in the tumor micro-environment  [1].  PD-L1 is one ligand for PD-1, an inhibitory immune checkpoint receptor that is expressed by activated and exhaused T cells. PD-1:PD-L1 interaction induces inhibition of T-cell receptor signaling, thereby preventing T-cell overstimulation and host damage [1].

 

Features of Raji-hPD-L1 cells:

  • Stable overexpression of the human PD-L1 gene
  • Constitutive expression of human CD19 and human CD20 at the cell surface
  • Stable expression of a resistance gene to Blasticidin at the cell surface

Applications for Raji-hPD-L1 cells:

  • ADCC target cells for anti-hPD-L1, anti-hCD19, or anti-hCD20 Abs
  • Negative control target cells in ADCC assays using Abs other than anti-hPD-L1, anti-hCD19, or anti-hCD20 Abs
  • Target cells for anti-hCD19-CD3 bispecific Abs

Validation of Raji-hPD-L1 cells:

 

References:

1. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.

Figures


Comparison of ADCC potency for native and engineered anti-human PD-L1 antibody isotypes: Raji-hPD-L1 cells were incubated with gradient concentrations of Anti-hPD-L1 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with targets cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Back to the top

Specifications

Quality control:

  • Human PD-L1 expression has been verified by flow-cytometry.
  • Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using InvivoGen’s anti-hPD-L1-hIgG1 antibody and Jurkat-NFAT Lucia™ CD16 reporter cell line.
  • The stability for 20 passages following thawing has been verified.
  • Raji-hPD-L1 cells are guaranteed mycoplasma-free.

These products are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

  • 1 vial of Raji-hPD-L1 cells (3-7 x 106 cells) in Freezing Medium.
  • 1 ml of Blasticidin (10 mg/ml). Store at 4 °C or at -20 °C.
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria and fungi. Store at -20 °C.

IMPORTANT: Cells are shipped frozen. If cells are not frozen upon arrival, contact InvivoGen immediately.

Shipped on dry ice Shipped on dry ice (Europe, USA & Canada)

Back to the top
Customer Service
& Technical Support
Shopping cart is empty